These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33495510)

  • 1. Design and optimisation of dendrimer-conjugated Bcl-2/x
    Patterson CM; Balachander SB; Grant I; Pop-Damkov P; Kelly B; McCoull W; Parker J; Giannis M; Hill KJ; Gibbons FD; Hennessy EJ; Kemmitt P; Harmer AR; Gales S; Purbrick S; Redmond S; Skinner M; Graham L; Secrist JP; Schuller AG; Wen S; Adam A; Reimer C; Cidado J; Wild M; Gangl E; Fawell SE; Saeh J; Davies BR; Owen DJ; Ashford MB
    Commun Biol; 2021 Jan; 4(1):112. PubMed ID: 33495510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
    Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
    Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
    Arulananda S; O'Brien M; Evangelista M; Jenkins LJ; Poh AR; Walkiewicz M; Leong T; Mariadason JM; Cebon J; Balachander SB; Cidado JR; Lee EF; John T; Fairlie WD
    Cell Death Discov; 2021 May; 7(1):122. PubMed ID: 34050131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
    Negi A; Voisin-Chiret AS
    Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
    Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
    Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
    Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
    Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
    Chen J; Zhou H; Aguilar A; Liu L; Bai L; McEachern D; Yang CY; Meagher JL; Stuckey JA; Wang S
    J Med Chem; 2012 Oct; 55(19):8502-14. PubMed ID: 23030453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma.
    Feeney OM; Ardipradja K; Noi KF; Mehta D; De Rose R; Yuen D; Johnston APR; Kingston L; Ericsson C; Elmore CS; Hufton R; Owen DJ; Ashford MB; Porter CJH
    J Control Release; 2022 Aug; 348():420-430. PubMed ID: 35636618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
    Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.
    Aguilar A; Zhou H; Chen J; Liu L; Bai L; McEachern D; Yang CY; Meagher J; Stuckey J; Wang S
    J Med Chem; 2013 Apr; 56(7):3048-3067. PubMed ID: 23448298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma.
    Yi H; Qiu MZ; Yuan L; Luo Q; Pan W; Zhou S; Zhang L; Yan X; Yang DJ
    Cancer Med; 2020 Jun; 9(12):4197-4206. PubMed ID: 32346976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL-X
    Judd AS; Bawa B; Buck WR; Tao ZF; Li Y; Mitten MJ; Bruncko M; Catron N; Doherty G; Durbin KR; Enright B; Frey R; Haasch D; Haman S; Haight AR; Henriques TA; Holms J; Izeradjene K; Judge RA; Jenkins GJ; Kunzer A; Leverson JD; Martin RL; Mitra D; Mittelstadt S; Nelson L; Nimmer P; Palma J; Peterson R; Phillips DC; Ralston SL; Rosenberg SH; Shen X; Song X; Vaidya KS; Wang X; Wang J; Xiao Y; Zhang H; Zhang X; Blomme EA; Boghaert ER; Kalvass JC; Phillips A; Souers AJ
    Sci Adv; 2024 Oct; 10(40):eado7120. PubMed ID: 39365864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
    Jin J; Xiong Y; Cen B
    Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers.
    England RM; Hare JI; Barnes J; Wilson J; Smith A; Strittmatter N; Kemmitt PD; Waring MJ; Barry ST; Alexander C; Ashford MB
    J Control Release; 2017 Feb; 247():73-85. PubMed ID: 28043863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
    Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
    Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
    Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
    J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.